Page 2 - Scientific Library
Crosstalk between cancer and immune cells: tumor escape
A crosstalk between cancer and immune cells is established during cancers. The immune system is able to fight against tumour cells (see my previous post "Immunosurveillance: Crosstalk between cancer and
Which Histone (De)Methyltransferase modulators to choose?
Histone Methyltransferases (ex. EZH1 and EZH2, and G9a) and their counter-parts (Histone demethylases like JARID1, the KDM4, and the JMJD family) have become promising targets for inhibitor screenings,
Is tumour immune evasion mediated by p53/miR-34/PDL1 interaction?
Tumour immune evasion can be mediated by a complex set of interaction involving p53, miR-34 and PDL1. This is the conclusion of a work by Cortez et al. and recently published in JCNI .
The
Cancer Immunotherapy: Generate your PD-L1 target cell line
In a recent post, I invited you to discover a cell
Post-Translational Modifications (PTM) of Tubulin
In this post, I'd like to take a look at the current understanding of tubulin PTMs, that include tyrosination/detyrosination, Δ2-tubulin formation, acetylation, phosphorylation, ubiquitination, glutamylation,
Screen for inhibitors of PD-1 signalling with a complete cellular assay system
Immunotherapy represents a field in Drug Discovery which is quickly developing and leading to significant progress in treatments of a number of diseases, especially cancer. The approach is based on inducing,
New - Continued use immunotherapy cell line expressing recombinant PD-1
New Reporter cell lines for Drug discovery and Immunotherapy checkpoint research
In the last few decades, in the field of Drug Discovery, Immunotherapy has gained more and more importance for the treatment of various diseases and in particular for certain types of